点击显示 收起
Center for Vaccine Development, University of Maryland School of Medicine, Baltimore
Dengue fever (DF) is rapidly evolving into one of the world's major infectious diseases [1]. DF is an acute flavivirus infection transmitted by several species of Aedes mosquitoes. Dengue virus has 4 antigenically related serotypes: DEN-1, DEN-2, DEN-3, and DEN-4. Infection with any 1 of the 4 serotypes can produce a broad spectrum of effects, including asymptomatic infection, mild febrile illness, classic DF, and the lethal dengue hemorrhagic fever/shock syndrome (DHF/DSS). Dengue virus has become impossible to eradicate and difficult to control, because of massive urbanization, overpopulation, ever-increasing regional and international travel, and failure to sustain Aedes aegypti control programs. Moreover, there is no specific treatment for DHF/DSS. Mortality rates vary from <1% to >30%, depending on diagnostic acumen and availability of intravenous fluids and blood for treatment of the hypovolemic shock caused by massive hemorrhage and capillary plasma leak [2].
An estimated 50100 million dengue infections and 500,000 DHF/DSS cases occur annually in the tropics, and DF is well known in North American and European travelers and military personnel [3]. In tropical areas where dengue virus is highly endemic, DHF/DSS is typically confined to children younger than age 15 years, with a mean age of 510 years. Dengue infection has spread progressively to most tropical countries during the past 40 years, particularly to countries in Southeast Asia, the western Pacific, and Latin America [1]. To illustrate, the number of cases of DF and DHF/DSS in the Philippines has increased 700% between the 1970s and the early 1990s. In Indonesia, dengue infection was recognized in only 2 cities in 1968; by 2001, it was reported in all of the nation's provinces and in 93% of its 310 districts. DHF is the second-most-frequent cause of pediatric admissions at Jakarta's largest public hospital, after acute respiratory infections. The spread of dengue virus from cities to rural areas has impeded the diagnosis and management of DHF/DSS; this, in turn, has resulted in higher case fatality rates, which may be as high as 30% in rural areas, compared with 1% in cities. The disease now occurs throughout most months of the year and is no longer confined to the 46-month rainy season. Prominent media attention and the fact that DHF/DSS affects poor and rich children alike have contributed to its notoriety. Dengue epidemics cause the population to panic and to overwhelm hospitals and outpatient clinics. There is near-universal agreement among policy makers in Southeast Asian countries that a dengue vaccine is urgently needed [4]. This sense of urgency is shared by the US military and the World Health Organization [5].
A key fact driving dengue vaccine development is that a primary infection with 1 serotype may induce long-term protective immunity to reinfection with the homologous serotype but only short-term immunity, lasting several months, to heterologous serotypes [6]. Dengue differs from other hemorrhagic infections in that dengue infection is more severe in individuals who have acquired dengue antibodies either passively, from their mothers before birth, or actively, from a previous dengue infection [79]. Antibody-dependent enhancement (ADE) has provided an explanatory hypothesis, whereby preexisting, cross-reactive dengue virus antibodies facilitate dengue virus entry into Fc-receptorbearing cells (e.g., macrophages), thereby increasing virus burden and disease severity [1012]. The secondary-infection hypothesis and ADE suggest that dengue vaccines must induce protective neutralizing antibodies to all 4 serotypes simultaneously rather than sequentially, to avoid enhancement of dengue illness after subsequent infection. Also, a tetravalent vaccine will better protect travelers and troops rapidly deployed to tropical areas where several dengue virus serotypes cocirculate.
For the past 20 years, live attenuated monovalent vaccine candidates, propagated and attenuated in primary and diploid cell cultures, have been evaluated in humans by US Army investigators [1316]. Most of these vaccine candidates were either underattenuated, making the volunteers ill, or overattenuated, lacking suitable immunogenicity. The proper balance between immunogenicity and reactogenicity was achieved by Halstead, through use of primary dog kidney (PDK) cell culture to grow the vaccine candidates [1719]. The Mahidol University group in Thailand and the US Army group at the Walter Reed Army Institute of Research (WRAIR) have each developed acceptably safe and immunogenic PDK-passaged monovalent vaccines representing each of the 4 dengue virus serotypes [2022]. Both research groups have combined their successful monovalent strains into several tetravalent vaccine formulations for phase 1/2 trials in North American adult volunteers [2325] or in Thai adults and children [26, 27]. To summarize the results of these trials: the vaccines were more reactogenic after the first of 2 or 3 vaccinations, and seroconversion to all 4 dengue serotypes in >80% of volunteers occurred only after the second or third booster inoculation, administered many months after the priming vaccination. The Mahidol vaccines appear to be unacceptably reactogenic in children [26]. One promising formulation of the WRAIR tetravalent vaccine is currently being tested in Thai children and infants. Industry support will be essential for any vaccine candidates selected for the prolonged and expensive field trials that lead to licensure.
Recombinant DNA technology has facilitated the development of live attenuated vaccines for dengue virus and other flaviviruses. The article by Durbin et al. [28] in this issue of the Journal of Infectious Diseases adds a valuable new chapter to the 70-year-old saga of dengue vaccine development. The authors have provided convincing evidence that their prototype vaccine candidate, rDEN430, has a promising future. The vaccine is derived from a cDNA clone of DEN-4 and contains a 30-nt deletion in the 3 untranslated region of the virus [29, 30]. It is safe, clinically well tolerated, robustly immunogenic, and genetically stable in healthy, adult US volunteers after a single inoculation. The low dose needed to induce immunity should make it economical to manufacture. The vaccine seems to be restricted in its ability to infect mosquitoes [31], and, therefore, there is little risk of loss of the attenuation phenotype that is possible after sustained transmission of live virus vaccines. The 30 mutation provides a genetic backbone for the creation of chimeric viruses containing the structural genes for the C protein, premembrane (prM) protein, and envelope (E) glycoprotein of DEN-1, DEN-2, and DEN-3. The E gene product binds to host cells and represents the major protective antigen [32]. Durbin et al.'s results justify construction and clinical trial of 30 chimeras expressing E antigens of each of the 3 remaining dengue serotypes and their final incorporation into a candidate tetravalent vaccine. Two important unanswered questions involve the duration of the neutralizing antibody response and whether virus-virus interference in a tetravalent formulation inhibits the antibody response to 1 or more dengue serotypes in the vaccine.
An equally promising advance is the ChimeriVax vaccine technology, developed by Acambis. The genes encoding the prM and E proteins of the licensed yellow fever vaccine virus 17D (YF-VAX) have been replaced with those of heterologous flaviviruses, including the 4 dengue serotypes [33, 34] and other flaviviruses [3538]. Phase 1 clinical trials of these chimeric vaccine candidates are under way.
Several other chimeric dengue vaccines are in the late stages of preclinical development [5], and the preclinical development of other vaccine candidates is in progress. These alternative candidates include purified, inactivated dengue virus [39]; infectious DNA or RNA; expression vectorbased and naked DNA; and recombinant subunit dengue vaccines [40].
Many research and public health questions remain unresolved. For example:
1. Can tetravalent vaccines consistently achieve acceptable reactogenicity and >80% antibody response to all 4 serotypes and in all populations at risk for dengue infection RNA sequence data indicate that the dengue viruses are evolving and diverging [41, 42]. The molecular basis of virulence and pathogenesis of DHF/DSS must be better understood, to ensure that vaccine development stays ahead of dengue virus evolution. The mechanisms of vaccine-induced protection need to be clarified in future field trials. The consensus immunogenic target of a neutralizing antibody response to all 4 serotypes in at least 80% of volunteers may not be appropriate in all populations and clinical settings.
2. Are tetravalent vaccines safe and immunogenic in flavivirus-seropositive persons There is a theoretical concern that prior natural infection (or vaccination) with a serologically related flavivirus, such as Japanese encephalitis virus (in Asia) or yellow fever virus, St. Louis encephalitis virus, or West Nile virus (in the Americas), would sensitize individuals and lead to more severe vaccine reactions than in flavivirus-naive persons. The benign clinical course and robust immune response in volunteers immunized with monovalent DEN-2 vaccine after vaccination against yellow fever [13, 14] provides some reassurance that severe reactions would not occur and that dengue titers may be enhanced.
3. Would tetravalent live-virus vaccines be safe and immunogenic in HIV-infected persons HIV infection is increasing in populations at risk for dengue infection, particularly in Southeast Asia. Attenuated live-virus vaccines are generally contraindicated in HIV-infected persons. With the exception of 1 patient, who recovered uneventfully from DHF [43], there have been no published reports of dengue infection in HIV-seropositive persons. Dengue vaccine candidates may need to be tested carefully in HIV-positive and other immunosuppressed individuals, but the ethics of such studies are problematic.
4. Do tetravalent vaccines elicit virus-enhancing antibody similar to that induced by wild-type dengue virus infection [10] If so, what is the clinical significance of such antibody [44]
5. How do the vaccine responses in infants and children differ from those in adults Infants often respond to wild-type dengue virus infection with few symptoms, and preadolescent children are less incapacitated by dengue infection than are adults. Similarly, PDK-attenuated vaccines, which tend to be reactogenic in adults, may be less reactogenic in infants and young children. Clinical attenuation as a function of decreasing age has, in fact, been noted in the first modern, tetravalent, live attenuated vaccine trial in dengue- and Japanese encephalitis virusseronegative children [26]. However, most children (60%) still had mild to moderate dengue-like illness after the first of 3 vaccinations, and seroconversion to the 4 serotypes in >80% of volunteers was achieved only after the third inoculation, at 12 months. A WRAIR PDK-attenuated vaccine formulation is currently undergoing a phase 1 trial in children and infants in Bangkok; I await the outcome with anticipation.
An opportunity now exists to put newly developed dengue vaccines into the field quickly. In July 2003, the Bill and Melinda Gates Foundation funded the Pediatric Dengue Vaccine Initiative (PDVI) for 5 years and US $55 million. The International Vaccine Institute in Seoul, South Korea, serves as the PDVI secretariat. A 4-point program will accelerate the development and field testing of dengue vaccines [45]. I am optimistic that field trials of 1 or more dengue vaccines will commence within 3 years in Latin America and in Southeast Asia. The licensing of a protective vaccine must come soon, if dengue is to be brought under control.
References
1. Gubler DJ. Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century. Trends Microbiol 2002; 10:1003. First citation in article
2. Henchal EA, Putnak JR. The dengue viruses. Clin Microbiol Rev 1990; 3:37696. First citation in article
3. Jelinek T, Muhlberger N, Harms G, et al. Epidemiology and clinical features of imported dengue fever in Europe: sentinel surveillance data from TropNetEurop. Clin Infect Dis 2002; 35:104752. First citation in article
4. DeRoeck D, Deen J, Clemens JD. Policymakers' views on dengue fever/dengue haemorrhagic fever and the need for dengue vaccines in four southeast Asian countries. Vaccine 2003; 22:1219. First citation in article
5. Almond J, Clemens J, Engers H, et al. Accelerating the development and introduction of a dengue vaccine for poor children, 58 December 2001, Ho Chi Minh City, VietNam. Vaccine 2002; 20:30436. First citation in article
6. Sabin A. Research on dengue in World War II. Amer J Trop Med 1952; 1:3050. First citation in article
7. Burke DS, Nisalak A, Johnson DE, Scott RM. A prospective study of dengue infections in Bangkok. Am J Trop Med Hyg 1988; 38:17280. First citation in article
8. Halstead SB, Nimmannitya S, Cohen SN. Observations related to pathogenesis of dengue hemorrhagic fever. IV. Relation of disease severity to antibody response and virus recovered. Yale J Biol Med 1970; 42:31128. First citation in article
9. Guzman MG, Kouri GP, Bravo J, Soler M, Vazquez S, Morier L. Dengue hemorrhagic fever in Cuba, 1981: a retrospective seroepidemiologic study. Am J Trop Med Hyg 1990; 42:17984. First citation in article
10. Kliks SC, Nisalak A, Brandt WE, Wahl L, Burke DS. Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. Am J Trop Med Hyg 1989; 40:44451. First citation in article
11. Halstead SB. Pathogenesis of dengue: challenges to molecular biology. Science 1988; 239:47681. First citation in article
12. Sullivan NJ. Antibody-mediated enhancement of viral disease. Curr Top Microbiol Immunol 2001; 260:14569. First citation in article
13. Bancroft WH, Scott RM, Eckels KH, et al. Dengue virus type 2 vaccine: reactogenicity and immunogenicity in soldiers. J Infect Dis 1984; 149:100510. First citation in article
14. Bancroft WH, Top FH, Eckels KH, Anderson JH, McCown JM, Russell PK. Dengue-2 vaccine: virological, immunological, and clinical responses of six yellow fever-immune recipients. Infect Immun 1981; 31:698703. First citation in article
15. Hoke CH, Malinoski FJ, Eckels KH, et al. Preparation of an attenuated dengue 4 (341750 Carib) virus vaccine. II. Safety and immunogenicity in humans. Am J Trop Med Hyg 1990; 43:21926. First citation in article
16. McKee KT Jr, Bancroft WH, Eckels KH, Redfield RR, Summers PL, Russell PK. Lack of attenuation of a candidate dengue 1 vaccine (45AZ5) in human volunteers. Am J Trop Med Hyg 1987; 36:43542. First citation in article
17. Halstead SB, Eckels KH, Putvatana R, Larsen LK, Marchette NJ. Selection of attenuated dengue 4 viruses by serial passage in primary kidney cells. IV. Characterization of a vaccine candidate in fetal rhesus lung cells. Am J Trop Med Hyg 1984; 33:67983. First citation in article
18. Halstead SB, Marchette NJ. Biologic properties of dengue viruses following serial passage in primary dog kidney cells: studies at the University of Hawaii. Am J Trop Med Hyg 2003; 69:511. First citation in article
19. Eckels KH, Scott RM, Bancroft WH, et al. Selection of attenuated dengue 4 viruses by serial passage in primary kidney cells. V. Human response to immunization with a candidate vaccine prepared in fetal rhesus lung cells. Am J Trop Med Hyg 1984; 33:6849. First citation in article
20. Edelman R, Tacket CO, Wasserman SS, et al. A live attenuated dengue-1 vaccine candidate (45AZ5) passaged in primary dog kidney cell culture is attenuated and immunogenic for humans. J Infect Dis 1994; 170:144855. First citation in article
21. Bhamarapravati N, Sutee Y. Live attenuated tetravalent dengue vaccine. Vaccine 2000; 18(Suppl 2):447. First citation in article
22. Kanesa-Thasan N, Edelman R, Tacket CO, et al. Phase 1 studies of Walter Reed Army Institute of Research candidate attenuated dengue vaccines: selection of safe and immunogenic monovalent vaccines. Am J Trop Med Hyg 2003; 69:1723. First citation in article
23. Edelman R, Wasserman SS, Bodison SA, et al. Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine. Am J Trop Med Hyg 2003; 69:4860. First citation in article
24. Kanesa-Thasan N, Sun W, Kim-Ahn G, et al. Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers. Vaccine 2001; 19:317988. First citation in article
25. Sun W, Edelman R, Kanesa-Thasan N, et al. Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates. Am J Trop Med Hyg 2003; 69:2431. First citation in article
26. Sabchareon A, Lang J, Chanthavanich P, et al. Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children. Ped Infect Dis J 2004; 23:99109. First citation in article
27. Sabchareon A, Lang J, Chanthavanich P, et al. Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses. Am J Trop Med Hyg 2002; 66:26472. First citation in article
28. Durbin AP, Whitehead SS, McArthur J, et al. rDEN430, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers. J Infect Dis 2005; 191:7108 (in this issue). First citation in article
29. Men R, Bray M, Clark D, Chanock RM, Lai CJ. Dengue type 4 virus mutants containing deletions in the 3 noncoding region of the RNA genome: analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in rhesus monkeys. J Virol 1996; 70:39307. First citation in article
30. Durbin AP, Karron RA, Sun W, et al. Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3-untranslated region. Am J Trop Med Hyg 2001; 65:40513. First citation in article
31. Troyer JM, Hanley KA, Whitehead SS, et al. A live attenuated recombinant dengue-4 virus vaccine candidate with restricted capacity for dissemination in mosquitoes and lack of transmission from vaccinees to mosquitoes. Am J Trop Med Hyg 2001; 65:4149. First citation in article
32. Anderson R, King AD, Innis BL. Correlation of E protein binding with cell susceptibility to dengue 4 virus infection. J Gen Virol 1992; 73:21559. First citation in article
33. Johnson BW, Chambers TV, Crabtree MB, Guirakhoo F, Monath TP, Miller BR. Analysis of the replication kinetics of the ChimeriVax-DEN 1, 2, 3, 4 tetravalent virus mixture in Aedes aegypti by real-time reverse transcriptase-polymerase chain reaction. Am J Trop Med Hyg 2004; 70:8997. First citation in article
34. Guirakhoo F, Pugachev K, Arroyo J, et al. Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates. Virology 2002; 298:14659. First citation in article
35. Beasley DW, Li L, Suderman MT, et al. Protection against Japanese encephalitis virus strains representing four genotypes by passive transfer of sera raised against ChimeriVax-JE experimental vaccine. Vaccine 2004; 22:37226. First citation in article
36. Johnson BW, Chambers TV, Crabtree MB, Arroyo J, Monath TP, Miller BR. Growth characteristics of the veterinary vaccine candidate ChimeriVax-West Nile (WN) virus in Aedes and Culex mosquitoes. Med Vet Entomol 2003; 17:23543. First citation in article
37. Monath TP, McCarthy K, Bedford P, et al. Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections. Vaccine 2002; 20:100418. First citation in article
38. Arroyo J, Miller C, Catalan J, et al. ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy. J Virol 2004; 78:12497507. First citation in article
39. Putnak R, Barvir DA, Burrous JM, et al. Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: immunogenicity and protection in mice and rhesus monkeys. J Infect Dis 1996; 174:117684. First citation in article
40. Pugachev KV, Guirakhoo F, Trent DW, Monath TP. Traditional and novel approaches to flavivirus vaccines. Int J Parasitol 2003; 33:56782. First citation in article
41. Trent DW, Grant JA, Monath TP, Manske CL, Corina M, Fox GE. Genetic variation and microevolution of dengue 2 virus in Southeast Asia. Virology 1989; 172:52335. First citation in article
42. Trent DW, Grant JA, Rosen L, Monath TP. Genetic variation among dengue 2 viruses of different geographic origin. Virology 1983; 128:27184. First citation in article
43. Watt G, Kantipong P, Jongsakul K. Decrease in human immunodeficiency virus type 1 load during acute dengue fever. Clin Infect Dis 2003; 36:10679. First citation in article
44. Guy B, Chanthavanich P, Gimenez S, et al. Evaluation by flow cytometry of antibody-dependent enhancement (ADE) of dengue infection by sera from Thai children immunized with a live-attenuated tetravalent dengue vaccine. Vaccine 2004; 22:356374. First citation in article
45. Halstead SB, Deen J. The future of dengue vaccines. Lancet 2002; 360:12435. First citation in article